In first M&A strike, Paul Stoffels lays out 5-year plan to turn Galapagos around

Five years may not seem long to turn around a struggling biotech. But that’s the time frame recently installed Galapagos CEO Paul Stoffels, M.D., has given himself to reorient the company around his mantra of: “Let’s focus on the patient.”